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Through N-acylation of - or -amino acid units by 2-(3-oxo-2,3-dihydro-1H-inden-5-yloxy)acetic 
acid using the method of N-hydroxysuccinimide esters new dipeptide indan-1-one derivatives were 
obtained. In general, the direct interaction of the acetic carboxyl group of the substrate with the 
amino group of the - or -dipeptide is a more productive strategy than the sequential peptidic 
condensation of the two amino acids. 
________________________________________________________________________________ 
Introduction 
Natural compounds with an indanone 
fragment, although relatively few in number, are 
very diverse both in functional groups present 
and in the biological activity. Among them 
(Figure 1), one can find toxic sesquiterpenes, 
named pterosins, contained in various fern 
species [1, 2] and usefull in diabet [3], 
osteoarthritis [4] and other diseases treatment; 
antibacterial polycondensed aromatic 
compounds such as indanonaftol B [5]; the 
biphenyl derivative 1 [6]; the dihydrofuranone 
derivative 2 [7]; as well as the carboxaldehyde 
derivative 3 with antitumor activity [8]. More 
generally, natural indanones or indanes 
can be considered as bio-inspiring 
or medicinal chemistry [9]. For example, 
indanone acetamides of type 4 were shown to 
exhibit promising antimicrobial and antifungal 
activity [10].  
A remarkable indane drug, used in the 
treatment of neurodegenerative disorders, is 
Ladostigil (TV-3326), a reductive amination 
derivative of 6-hydroxyindan-1-one [11]. With 
the view to extending the scope of such bio-
active compounds, methodological studies of 
the functionalization of the indanone core thus 
deserve particular attention. 
Along this line, we previously reported 
on the functionalization of 6-hydroxyindan- 
1-one with amino acid fragments through an 
oxyacetic  linker,  showing  that  the  method  of 
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Figure 1. Natural and synthetic indanone derivatives. 
 
hydroxysuccinimide esters [12, 13] is more 
efficient than the carbonylimidazole 
condensation method [14].  
The present report describes the 
beneficial use of hydroxysuccinimide esters for 
the synthesis of - or -dipeptide derivatives 
of 2-(3-oxo-2,3-dihydro-1H-inden-5-yloxy)acetic 
acid. 
 
Results and discussion 
Two possible strategies for the 
preparation of the - or -dipeptide targets can 
be distinguished: through either direct 
interaction of the indanone substrate with the 
terminal amino group of the preformed 
dipeptide, or sequential condensation of the two 
amino acids. The first method is obviously 
convenient but the second one can give more 
variety of products. 
In order to explore the one-step strategy, 
the N-hydroxysuccinimide activated ester 6 was 
generated in situ from the acid 5 (Scheme 1), 
before addition of different dipeptides with a 
free amino function to obtain the target 
compounds 7a-i. TLC monitoring showed that 
the overall conversion was complete. Moderate 
to poor isolated yields were obtained in some 
cases (Scheme 1) because of the high solubility 
of the substance in the aqueous reaction medium 
(see Experimental part). 
The two-step method was tested on 
tryptophan and methionine derivatives, the 
expected low solubility these substances a priori 
can help to avoid the losses during workup and 
allowing a more accurate evaluation of the 
reaction efficiency. So, the carboxylic group of 
compounds 8a,b (Scheme 2, the synthesis was 
described in ref. [14]) was converted into the 
corresponding N-hydroxysuccinimide activated 
ester 9. Without further purification, the latter 
was treated with another amino acid to give 
dipeptides 7j-n. The moderate overall yields of  
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Scheme 1. One-pot synthesis of the -dipeptide derivatives 7a-h and -dipetide derivative 7i from the acid 5 and the 
corresponding pre-formed dipeptides. 
 
products 7j-n were due the low yields of the 
corresponding initial transformation 58 (see 
in ref. [14]), and the yield of the conversion 
57 after two steps was only 26 % for 
dipeptide 7j, 33 % – for 7k, 25 % – for 7l, and 
42 % – for 7m, 34 % – for 7n respectively. 
All spectral data confirmed the structure 
of the products 7 (see Experimental part). The 
1H NMR spectra in DMSO-d6 solutions did not 
allow detection of the COOH signals due to fast 
exchange; but the IR spectra displayed the 
corresponding wide intense absorption band of 
the O–H bond, along with a maximum 
absorption of the N–H bond near to 3300 cm–1. 
The syntheses were performed from 
optically pure amino acids, except the synthesis 
of 7l for which optically pure L-tryptophan and 
racemic DL-alanine were used. So, substance 7l 
was obtained as a mixture of equal amounts of 
two diastereomers, as shown by 1H NMR 
spectroscopy.  
 
 
 
Scheme 2. Two-step synthesis of the -dipeptide derivatives 7j-m and -dipetide derivative 7n from the acid 5 by 
consecutive reactions with two amino acids. 
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Conclusions 
It was shown that the dipeptide 
derivatives of 2-(3-oxo-2,3-dihydro-1H-inden-
5-yloxy)acetic acid can be obtained by either 
consecutive reactions of the two amino acids, or 
immediately from a pre-formed dipeptide 
precursor. Nonetheless, the one-step strategy 
appears more efficient: both more convenient 
and more productive. A more exact quantitative 
estimate can be obtained subsequently using 
parallel synthesis of series of identical 
dipeptides by these two methods. 
The developed synthetic procedures can 
be useful for obtaining a number of new 
indanone amino acid derivatives in order to 
study their optical characteristics and biological 
activity. 
 
Experimental part 
The reaction progress and identities of 
the products were controlled with TLC on 
Merck F254 plates using a chloroform:methanol 
(19:1, v/v) eluting system. 
1H and 13C NMR spectra were recorded 
on a Varian 400 spectrometer operating at 
400 MHz for 1H and 100 MHz for 13C. NMR 
chemical shifts are reported in ppm, in the  
scale and are referenced using TMS as internal 
standard.  
FTIR spectra were recorded on a 
Thermo Nicolet Nexus 470 spectrometer in KBr 
pellets.  
Melting points were determined using a 
Leica Galen III Kofler-type melting point 
microscope, and were uncorrected.  
The synthesis of 5 was performed using 
a previously described procedure [14, 15]; for 
the synthesis of the amino acid derivatives 8, 
see ref. [14].  
General procedure for N-acylation 
through the N-hydroxysuccinimide ester 
method. To a solution of the acid 5, 8a or 8b 
(1.5 mmol) and N-hydroxysuccinimide (0.23 g, 
2 mmol) in absolute dioxane (10 mL) dicyclo-
hexylcarbodiimide (0.41 g, 2 mmol) was added 
at room temperature under vigorous stirring. 
The mixture was stirred at room temperature for 
2–3 h until an activated ester was formed (TLC 
monitoring); then a solution of the corres-
ponding amino acid or dipeptide (1.75 mmol) 
and NaHCO3 (0.25 g, 3 mmol) in water (10 mL) 
was added (the amino acids and dipeptide were 
been used in free amine form and not in 
protonated form). The reaction mixture was 
stirred at room temperature for 2–3 h (TLC 
monitoring). After the process was finished, the 
dicyclohexylurea precipitate was filtered off. 
The filtrate was poured into water (50 mL) and 
the solution was acidified (to pH 4–5) with 
dilute HCl. The precipitate formed was filtered 
off, recrystallized from a i-PrOH:water 1:1 
mixture. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}glycyl-
glycine 7a. Yield 0.26 g, 0.81 mmol, 54 %. Mp 
229–230°C. 1H NMR (DMSO-d6),  (ppm): 
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2.63 (br. s, 2H, H2-3), 3.00 (br. s, 2H, H2-2), 
3.65–3.85 (br. s, 4H, 2 NHCH2), 4.59 (s, 2H, 
OCH2CO), 7.10 (br. s, 1H, H-7), 7.33 (br. d, 
J=6.8 Hz, 1H, H-5), 7.50 (d, J=6.8 Hz, 1H, H-
4), 8.23 (br. s, 1H, NH), 8.39 (br. s, 1H, NH). 
13C NMR (DMSO-d6),  (ppm): 25.1, 37.1, 
41.1, 42.0, 67.6, 106.7, 123.8, 128.3, 138.2, 
148.8, 157.7, 168.2, 169.4, 171.5, 206.2. IR 
(KBr),  (cm–1): 3289, 3099, 2934, 1714, 1671, 
1633, 1569, 1492, 1438, 1288, 1253, 1070, 834, 
746, 558. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}glycyl-
alanine 7b. Yield 0.24 g, 0.72 mmol, 48 %. Mp 
202–203°C. 1H NMR (DMSO-d6),  (ppm): 
1.25 (d, J=7.0 Hz, 3H, CHCH3), 2.63 (br. s, 2H, 
H2-3), 3.00 (br. s, 2H, H2-2), 3.72–3.85 (br. s, 
4H, NHCH2), 4.16–4.25 (m, 1H, CHCH3), 4.59 
(s, 2H, OCH2CO), 7.09 (br. s, 1H, H-7), 7.32 
(br. d, J=8.0 Hz, 1H, H-5), 7.50 (d, J=8.0 Hz, 
1H, H-4), 8.24 (d, J=7.0 Hz, 1H, NHCH), 8.32 
(m, 1H, NHCH2). 13C NMR (DMSO-d6),  
(ppm): 17.6, 25.1, 37.0, 41.8, 48.0, 67.5, 106.8, 
123.8, 128.2, 138.2, 148.8, 157.7, 168.1, 168.6, 
174.4, 206.4. IR (KBr),  (cm–1): 3284, 3089, 
2928, 1706, 1665, 1648, 1561, 1491, 1438, 
1285, 1224, 1065, 835, 720, 559. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}glycyl-
valine 7c. Yield 0.25 g, 0.69 mmol, 46 %. Mp 
159–159°C. 1H NMR (DMSO-d6),  (ppm): 
0.85 (br. s, 6H, CHCH(CH3)2), 1.98–2.09 (m, 
1H, CHCH(CH3)2), 2.62 (br. s, 2H, H2-3), 2.99 
(br. s, 2H, H2-2), 3.80–3.91 (br. s, 4H, NHCH2), 
4.11–4.20 (m, 1H, CHCH(CH3)2), 4.58 (s, 2H, 
OCH2CO), 7.09 (br. s, 1H, H-7), 7.32 (br. d, 
J=6.0 Hz, 1H, H-5), 7.50 (d, J=6.0 Hz, 1H, H-
4), 8.04 (d, J=6.8 Hz, 1H, NHCH), 8.32 (m, 1H, 
NHCH2). 13C NMR (DMSO-d6),  (ppm): 18.3, 
19.5, 25.1, 30.4, 37.0, 41.9, 57.7, 67.5, 106.6, 
123.8, 128.2, 138.2, 148.8, 157.7, 168.1, 169.0, 
173.4, 206.2. IR (KBr),  (cm–1): 3293, 3057, 
2965, 2929, 1707, 1663, 1544, 1490, 1284, 
1224, 1067, 837, 559. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}glycyl-
leucine 7d. Yield 0,45 g, 1.2 mmol, 80 %. Mp 
131–132°C. 1H NMR (DMSO-d6),  (ppm): 0.83 
(d, J=6.0 Hz, 3H, CH3), 0.87 (d, J=6.0 Hz, 3H, 
CH3), 1.51 (t, J=6.6 Hz, 2H, CHCH2CH(CH3)2), 
1.57–1.67 (m, 1H, CHCH2CH(CH3)2), 2.63 
(br. t, J=4.8 Hz, 2H, H2-3), 3.01 (br. t, J=4.8 Hz, 
2H, H2-2), 3.81 (br. d, J=5.0 Hz, NHCH2), 4.25 
(br. q, J=7.0 Hz, CHCH2CH(CH3)2), 4.59 (s, 
2H, OCH2CO), 7.11 (br. s, 1H, H-7), 7.32 (br. d, 
J=8.2 Hz, 1H, H-5), 7.50 (d, J=8.2 Hz, 1H, H-
4), 8.24 (d, J=7.0 Hz, 1H, NHCH), 8.32 (br. t, 
J=5.0 Hz, 1H, NHCH2). 13C NMR (DMSO-d6), 
 (ppm): 21.8, 23.2, 24.7, 25.1, 37.0, 41.8, 50.7, 
67.6, 106.8, 123.8, 128.2, 138.2, 148.8, 157.7, 
168.1, 168.8, 174.4, 206.4. IR (KBr),  (cm–1): 
3303, 2958, 2928, 1707, 1664, 1545, 1490, 
1284, 1224, 1067, 837. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}glycyl-
tyrosine 7e. Yield 0.51 g, 1.2 mmol, 80 %. Mp 
138–139°C. 1H NMR (DMSO-d6),  (ppm): 
2.64 (br. t, J=5.2 Hz, 2H, H2-3), 2.76 (dd, 
J=13.6 Hz, J=9.0 Hz, 1H, CH–CH(COOH)), 
2.92 (dd, J=13.6 Hz, J=4.7 Hz, 1H, CH–
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CH(COOH)), 3.01 (br. t, J=5.2 Hz, 2H, H2-3), 
3.71 (dd, J=16.5 Hz, J=5.7 Hz, 1H, NH–CH–
CONH), 3.81 (dd, J=16.5 Hz, J=5.7 Hz, 1H, 
NH–CH–CONH), 4.30–4.37 (m, 1H, CH2–
CH(COOH)), 4.58 (s, 2H, OCH2CO), 6.64 (d, 
J=8.2 Hz, 2Н, Н-3,5 (4-НОС6Н4)), 6.99 (d, 
J=8.2 Hz, 2Н, Н-2,6 (4-НОС6Н4)), 7.11 (br. s, 
1H, H-7), 7.33 (br. d, J=8.6 Hz, H-5), 7.50 (d, 
J=8.6 Hz, H-4), 8.15 (d, J=7.8 Hz, 1H, NHCH), 
8.31 (t, J=5.7 Hz, 1H, NHCH2). 13C NMR 
(DMSO-d6),  (ppm): 25.2, 36.6, 37.1, 41.9, 
54.4, 67.5, 106.8, 115.4, 123.9, 127.9, 130.5, 
138.2, 148.8, 156.3, 157.7, 168.1, 168.7, 173.4, 
186.9, 206.4. IR (KBr),  (cm–1): 3291, 2925, 
1706, 1662, 1547, 1516, 1490, 1438, 1284, 
1247, 1064, 835, 558. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}alanyl-
valine 7f. Yield 0.28 g, 0.75 mmol, 50 %. Mp 
174–175°C. 1H NMR (DMSO-d6),  (ppm): 
0.81–0.87 (m, 6H, CHCH(CH3)2), 1.99–2.10 
(m, 1H, CHCH(CH3)2), 1.25 (d, J=6.6 Hz, 3H, 
CHCH3), 2.63 (m, 2H, H2-3), 3.00 (m, 2H, H2-
2), 4.18 (br. t, J=6.5 Hz, 1H, CHCH(CH3)2), 
4.59 (m, 3H, CHCH3, OCH2CO), 7.08 (br. s, 
1H, H-7), 7.30 (br. d, J=8.2 Hz, H-5), 7.49 (d, 
J=8.2 Hz, H-4), 8.14 (d, J=7.0 Hz, 1H, NH), 
8.19 (d, J=7.0 Hz, 1H, NH). 13C NMR (DMSO-
d6),  (ppm): 18.0, 19.5, 25.1, 30.5, 37.0, 48.2, 
57.3, 67.3, 106.3, 123.8, 128.2, 138.2, 148.7, 
157.7, 167.2, 172.6, 173.3, 206.4. IR (KBr),  
(cm–1): 3277, 3068, 2967, 2934, 1740, 1701, 
1654, 1549, 1491, 1443, 1267, 1227, 1077, 834, 
676, 561. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}alanyl-
methionine 7g. Yield 0.20 g, 0.50 mmol, 33 %. 
Mp 82–83°C. 1H NMR (DMSO-d6),  (ppm): 
1.25 (br. s, 3H, CHCH3), 1.79–2.06 (m, 5H, 
CH2СН2SСН3), 2.44 (m, 2H, CH2СН2SСН3), 
2.63 (br. s, 2H, H2-3), 3.00 (br. s, 2H, H2-2), 
4.32 (m, 1H, NHCHCO), 4.41 (m, 1H, 
NHCHCO), 4.59 (s, 2H, OCH2CO), 7.10 (br. s, 
1H, H-7), 7.33 (br. d, J=6.0 Hz, 1H, H-5), 7.50 
(d, J=6.0 Hz, 1H, H-4), 8.13 (br. s, 1H, NH), 
8.27 (br. s, 1H, NH). 13C NMR (DMSO-d6),  
(ppm): 15.0, 25.1, 30.1, 31.2, 37.0, 41.2, 48.4, 
51.3, 67.4, 106.6, 123.8, 128.2, 138.2, 148.7, 
157.8, 167.3, 172.4, 173.6, 206.4. IR (KBr),  
(cm–1): 3311, 3064, 2922, 1724, 1690, 1541, 
1490, 1438, 1284, 1251, 1178, 1068, 837, 559. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}alanyl-
tryptophane 7h. Yield 0.35 g, 0.76 mmol, 51 %. 
Mp 118–119°C. 1H NMR (DMSO-d6),  (ppm): 
1.08 (d, J=6.0 Hz, 1.5H, CHCH3), 1.23 (d, 
J=6.0 Hz, 1.5H, CHCH3), 2.62 (br. s, 2H, H2-3), 
2.95–3.09 (m, 3H, H2-2, CH(indol-3-yl)), 
3.14–3.23 (m, 1H, CH(indol-3-yl)), 4.32–4.58 
(m, 2H, 2 NHCHCO), 4.57 (m, 2H, OCH2CO), 
6.97 (br. t, J=6.6 Hz, 1Н, Н-5 (indol-3-yl)), 
7.01–7.09 (m, 2H, H-7, Н-6 (indol-3-yl)), 7.14 
(d, J=13.5 Hz, 1H, H-5), 7.27–7.34 (m, 2H, H-
4, Н-2 (indol-3-yl)), 7.47 (d, J=8.0 Hz, 1Н, Н-
4 (indol-3-yl)), 7.50–7.55 (m, 1Н, Н-7 (indol-
3-yl)), 8.10–8.19 (m, 1H, NH), 8.26 and 8.30 
(two d, J=6.7 Hz, 1H, NH), 10.87 (br. s, 1H, NН 
(indol-3-yl)). 13C NMR (DMSO-d6),  (ppm): 
18.8, 25.2, 27.4, 37.1, 48.1, 53.5, 67.4, 106.7, 
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110.2, 111.8, 118.6, 118.8, 121.3, 123.9, 124.1, 
127.7, 128.3, 136.5, 138.2, 147.3, 148.8, 157.8, 
167.3, 173.6, 206.4. IR (KBr),  (cm–1): 3337, 
3058, 2927, 1686, 1665, 1560, 1490, 1277, 
1220, 1099, 745, 559.  
N-{[(1-oxoindan-6-yl)oxy]acetyl}alanyl-
-alanine 7i. Yield 0.27 g, 0.78 mmol, 52 %. 
Mp 117–118°C. 1H NMR (DMSO-d6),  (ppm): 
1.20 (d, J=6.0 Hz, 3H, CHCH3), 2.35 (br. t, 
J=6.0 Hz, 2H, NHCH2CH2), 2.62 (br. s, 2H, H2-
3), 2.99 (br. s, 2H, H2-2), 3.23 (br. t, J=6.0 Hz, 
2H, NHCH2CH2), 4.29 (br. t, J=6.6 Hz, 1H, 
CHCH(CH3)2), 4.57 (s, 2H, OCH2CO), 7.06 
(br. s, 1H, H-7), 7.30 (br. d, J=8.0 Hz, 1H, H-5), 
7.48 (d, J=8.0 Hz, 1H, H-4), 8.13 (br. s, 1H, 
NHCH2), 8.14 (br. d, J=6.6 Hz, 1H, NH). 
13C NMR (DMSO-d6),  (ppm): 18.9, 25.1, 
34.2, 35.3, 37.0, 48.3, 67.3, 106.3, 123.9, 128.2, 
138.2, 148.7, 157.7, 167.3, 172.3, 173.3, 206.5. 
IR (KBr),  (cm–1): 3291, 2929, 1719, 1693, 
1664, 1627, 1546, 1492, 1286, 1227, 1075, 833. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
methionyltryptophan 7j. Yield 0.26 g, 
0.50 mmol, 33 %. Mp 109–110°C. 1H NMR 
(DMSO-d6),  (ppm): 1.67–2.10 (m, 5H, 
CH2СН2SСН3), 2.62 (br. t, J=5.4 Hz, 2H, H2-3), 
2.47 (m, 2H, CH2СН2SСН3), 2.98–3.13 (m, 3H, 
H2-2, CH(indol-3-yl)), 3.18–3.25 (m, 1H, 
CH(indol-3-yl)), 4.43–4.61 (m, 4H, OCH2CO, 
2 NHCHCO), 6.94 (br. t, J=7.4 Hz, 1Н, Н-5 
(indol-3-yl)), 7.01 (br. t, J=7.4 Hz, 1Н, Н-6 
(indol-3-yl)), 7.05–7.13 (m, 2H, H-5,7), 7.24–
7.32 (m, 2H, H-4, Н-2 (indol-3-yl)), 7.42 (d, 
J=8.5 Hz, 1Н, Н-4 (indol-3-yl)), 7.49–7.54 (m, 
1Н, Н-7 (indol-3-yl)), 8.05–8.21 and 8.32–8.41 
(two m, 1.5 and 0.5 H, 2 NH), 10.74 (br. s, 1H, 
NН (indol-3-yl)). 13C NMR (DMSO-d6),  
(ppm): 15.0, 25.1, 29.7, 32.5, 36.9, 51.8, 53.4, 
62.4, 67.2, 106.5, 110.0, 111.8, 118.5, 118.8, 
121.3, 123.7, 124.0, 127.6, 128.3, 136.5, 138.2, 
148.7, 157.7, 167.7, 171.0, 173.6, 206.4. IR 
(KBr),  (cm–1): 3324, 3057, 2922, 1701, 1665, 
1533, 1489, 1442, 1277, 1220, 1061, 837, 745, 
560. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
tryptophanylglycine 7k. Yield 0.39 g, 
0.87 mmol, 58 %. Mp 139–140°C. 1H NMR 
(DMSO-d6),  (ppm): 2.63 (br. s, 2H, H2-3), 
3.01–3.25 (m, 4H, H2-2, CH2(indol-3-yl)), 3.73 
(br. s, 2H, NHCH2), 4.40–4.52 (m, 2H, 
OCH2CO), 4.62–4.71 (m, 1H, NHCHCO), 6.93 
(br. t, J=6.0 Hz, 1Н, Н-5 (indol-3-yl)), 6.99–
7.05 (m, 2H, H-7, Н-6 (indol-3-yl)), 7.08–7.14 
(m, 2H, H-5, Н-2 (indol-3-yl)), 7.30 (d, 
J=7.0 Hz, 1H, H-4), 7.38 (d, J=7.6 Hz, 1Н, Н-4 
(indol-3-yl)), 7.57 (d, J=7.6 Hz, 1Н, Н-7 
(indol-3-yl)), 7.94 (d, J=7.4 Hz, 1H, NH), 8.31–
8.35 (m, 1H, NH), 10.64 (br. s, 1H, NН (indol-
3-yl)). 13C NMR (DMSO-d6),  (ppm): 25.1, 
28.0, 37.0, 41.2, 53.5, 67.5, 106.6, 110.2, 111.8, 
118.62, 121.2, 123.5, 124.2, 127.8, 128.2, 
136.4, 138.1, 148.7, 157.6, 167.6, 171.6, 171.9, 
206.2. IR (KBr),  (cm–1): 3313, 3057, 2927, 
1711, 1664, 1541, 1489, 1437, 1278, 1221, 
1063, 835, 795, 743, 559. 
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N-{[(1-oxoindan-6-yl)oxy]acetyl}-
tryptophanylalanine 7l. Yield 0.30 g, 
0.65 mmol, 43 %. Mp 139–141°C. 1H NMR 
(DMSO-d6),  (ppm): 1.18 (br. s, 1.5H, CHCH3), 
1.29 (br. s, 1.5H, CHCH3), 2.63 (br. s, 2H, H2-
3), 2.96–3.29 (m, 2H, H2-2, CH2(indol-3-yl)), 
4.10–4.29 (m, 1H, NHCHCO), 4.42–4.72 (m, 
3H, OCH2CO, NHCHCO), 6.91–7.23 (m, 5H, 
H-5,7, Н-2,5,6 (indol-3-yl)), 7.30–7.37 (m, 
2H, H-4), 7.42–7.49 (m, 1Н, Н-4 (indol-3-yl)), 
7.56–7.66 (m, 1Н, Н-7 (indol-3-yl)), 8.00–8.19 
(m, 1H, NH), 8.30–8.47 (m, 1H, NH), 10.82 
(br. s, 1H, NН (indol-3-yl)). 13C NMR (DMSO-
d6),  (ppm): 17.2, 25.2, 28.1, 37.0, 48.2, 53.3, 
67.4, 106.7, 109.9, 111.6, 118.6, 118.8, 121.2, 
123.5, 124.2, 127.8, 128.2, 136.5, 138.2, 148.5, 
157.4, 167.4, 171.2, 174.5, 206.4. IR (KBr),  
(cm–1): 3316, 3057, 2927, 1668, 1532, 1489, 
1445, 1277, 1221, 1061, 836, 745, 559. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
tryptophanylmethionine 7m. Yield 0.57 g, 
1.1 mmol, 73 %. Mp 111–112°C. 1H NMR 
(DMSO-d6),  (ppm): 1.83–2.05 (m, 5H, 
CH2СН2SСН3), 2.17–2.32 (m, 1H, CHСН2SСН3), 
2.40–2.50 (m, 1H, CHСН2SСН3), 2.63 (m, 2H, 
H2-3), 2.96–3.08 (m, 3H, H2-2, CH(indol-3-
yl)), 3.09–3.22 (m, 1H, CH(indol-3-yl)), 4.23–
4.30 (m, 0.5H, CH(CH2)2SСН3), 4.32–4.39 (m, 
0.5H, CH(CH2)2SСН3), 4.44–4.59 (m, 2H, 
OCH2CO), 4.59–4.73 (m, 1H, CHCH2(indol-3-
yl), 6.95 (br. t, J=7.6 Hz, 1Н, Н-5 (indol-3-yl)), 
7.01–7.08 (m, 2H, H-7, Н-6 (indol-3-yl)), 7.12–
7.22 (m, 2H, H-5, Н-2 (indol-3-yl)), 7.31 (d, 
J=8.0 Hz, 1H, H-4), 7.44 (d, J=8.0 Hz, 1Н, Н-4 
(indol-3-yl)), 7.62 (d, J=8.0 Hz, 1Н, Н-7 
(indol-3-yl)), 8.09 (d, J=8.0 Hz, 0.5H, NH), 
8.13 (d, J=8.0 Hz, 0.5H, NH), 8.42–8.48 (m, 
1H, NH), 10.80–10.87 (m, 1H, NН (indol-3-
yl)). 13C NMR (DMSO-d6),  (ppm): 14.9, 25.1, 
30.1, 31.2, 37.0, 51.6, 53.6, 66.8, 67.5, 106.9, 
110.1, 111.8, 118.8, 118.9, 121.4, 123.7, 124.5, 
127.9, 128.4, 136.5, 138.2, 148.7, 157.7, 167.5, 
171.7, 173.6, 206.3. IR (KBr),  (cm–1): 3320, 
3057, 2922, 2853, 1663, 1534, 1489, 1438, 
1277, 1221, 1062, 871, 744, 559. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
tryptophanyl--alanine 7n. Yield 0.44 g, 
0.95 mmol, 63 %. Mp 126–127°C. 1H NMR 
(DMSO-d6),  (ppm): 2.32 (t, J=7.0 Hz, 2H, 
NHCH2CH2), 2.64 (br. t, J=5.6 Hz, 2H, H2-3), 
2.95–3.06 (3H, m, H2-2, CH(indol-3-yl)), 3.12 
(dd, J=14.4 Hz, J=5.0 Hz, 1H, CH(indol-3-yl)), 
3.19–3.28 (m, 2H, NHCH2CH2), 4.45–4.57 (m, 
3H, OCH2CO, CHCH2(indol-3-yl), 6.94 (br. t, 
J=7.6 Hz, 1Н, Н-5 (indol-3-yl)), 7.02–7.07 (m, 
2H, H-7, Н-6 (indol-3-yl)), 7.11 (br. s, 1H, Н-2 
(indol-3-yl)), 7.19 (dd, J=8.0 Hz, J=2.4 Hz, 1H, 
H-5), 7.31 (d, J=8.0 Hz, 1H, H-4), 7.45 (d, 
J=7.6 Hz, 1Н, Н-4 (indol-3-yl)), 7.58 (d, 
J=7.6 Hz, 1Н, Н-7 (indol-3-yl)), 8.09 (d, 
J=8.0 Hz, 1H, NH), 8.17 (br. t, J=5.0 Hz, 1H, 
NH), 10.81 (s, 1H, NН (indol-3-yl)). 13C NMR 
(DMSO-d6),  (ppm): 25.1, 28.3, 34.2, 35.4, 
37.0, 53.6, 67.3, 106.7, 110.1, 111.6, 118.7, 
118.9, 121.4, 123.8, 124.1, 127.7, 128.2, 136.5, 
138.2, 148.7, 157.6, 167.5, 171.5, 173.4, 206.5. 
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IR (KBr),  (cm–1): 3297, 3058, 2926, 1701, 
1665, 1560, 1534, 1438, 1279, 1222, 1186, 
1063, 836, 743, 559. 
 
References 
[1] Kuroyanagi M, Fukuoka M, Yoshihira K, 
Natori S. Chemical and toxicological studies on bracken 
fern, Pteridium aquilinum var. latiusculum. III. Further 
characterization of pterosins and pterosides, 
sesquiterpenes and the glucosides having 1-indanone 
skeleton, from the rhizomes. Chem. Pharm. Bull. 1979; 
27(3): 592-601. 
[2] Finkielsztein LM, Alesso EN, Lanta B, 
Aguirre JM, Moltrasio GY. A simple synthetic route to 
pterosin F and other pterosins. J. Chem. Research (S) 
1999; 406. 
[3] Hsu FL, Huang CF, Chen YW, Yen YP, 
Wu CT, Uang BJ, Yang RS, Liu SH. Antidiabetic effects 
of pterosin A, a small-molecular-weight natural product, 
on diabetic mouse models. Diabetes. 2013; 62(2): 628-38. 
[4] Yahara Y, Takemori H, Okada M, 
Kosai A, Yamashita A, Kobayashi T, Fujita K, Itoh Y, 
Nakamura M, Fuchino M, Kawahara N, Fukui N, 
Watanabe A, Kimura T, Tsumaki N. Pterosin B prevents 
chondrocyte hypertrophy and osteoarthritis in mice by 
inhibiting Sik. Nature Commun. 2016; 7: 10959. 
[5] Bycroft BW, Payne DJ. Dictionary of 
Antibiotics and Related Substances. CRC Press; 2013, 
p. 1006.  
[6] Okpekon T, Millot M, Champy P, 
Gleye C, Yolou S, Bories C, Loiseau P, Laurens A, 
Hocquemiller R. A novel 1-indanone isolated from Uvaria 
afzelii roots. Nat. Prod. Res. 2009; 23(10): 909-915. 
[7] Rukachaisirikul V, Buadam S, 
Sukpondma Y, Phongpaichit S, Sakayaroj J, Hutadilok-
Towatana N. Indanone and mellein derivatives from the 
Garcinia-derived fungus Xylaria sp. PSU-G12. 
Phytochem. Lett. 2013; 6(1): 135-138. 
[8] Nagle DG, Zhou Y-D, Park PU, Paul VJ, 
Rajbhandari I, Duncan CJG, Pasco DS. A New Indanone 
from the Marine Cyanobacterium Lyngbya majuscule 
That Inhibits Hypoxia-Induced Activation of the VEGF 
Promoter in Hep3B Cells. J. Nat. Prod. 2000; 63(10): 
1431-1433.  
[9] Ahmed N. Synthetic Advances in the 
Indane Natural Product Scaffolds as Drug Candidates: A 
Review. Studies in Natural Products Chemistry 2016; 51: 
383-434. 
[10] Patel VK, Dhrubo JS, Patel CN. Anti-
microbial and antifungal screening of indanone acetic 
acid derivatives. J. Chem. Pharm. Res. 2010; 2(2): 50-56. 
[11] Weinstock M, Bejar C, Wang RH, 
Poltyrev T, Gross A, Finberg JP, Youdim MB. TV3326, a 
novel neuroprotective drug with cholinesterase and 
monoamine oxidase inhibitory activities for the treatment 
of Alzheimer's disease. J. Neural. Transm. Suppl. 2000; 
(60): 157-69. 
[12] Anderson GW, Zimmerman JE, 
Callahan FM. N-Hydroxysuccinimide Esters in Peptide 
Synthesis. J. Am. Chem. Soc. 1963; 85(19): 3039. 
[13] Gershkovich AA, Kibirev VK. 
Chemical Synthesis of Peptides [in Russian]. Kyiv: 
Naukova Dumka; 1992, pp. 38-44. 
[14] Shilin SV, Lenko IN, Shablykina OV, 
Khilya VP. 6-Oxyindan-1-ones with amino acid 
fragments. Fr. Ukr. J. Chem. 2018; 6(2): 18-26. 
[15] Koelsch FC, Scheiderbauer RA. The 
Tautomerism of Indene. J. Am. Chem. Soc. 1943; 65(12): 
2311-2314. 
 
